Fiona Gaughran
Gaughran, Fiona.
VIAF ID: 308748300 (Personal)
Permalink: http://viaf.org/viaf/308748300
Preferred Forms
- 100 0 _ ‡a Fiona Gaughran
-
- 100 1 _ ‡a Gaughran, Fiona
-
- 100 1 _ ‡a Gaughran, Fiona
- 100 1 _ ‡a Gaughran, Fiona
- 100 1 _ ‡a Gaughran, Fiona
-
4xx's: Alternate Name Forms (3)
Works
Title | Sources |
---|---|
Gene polymorphisms potentially related to the pharmacokinetics of clozapine: a systematic review | |
Glasgow Antipsychotic Side-effects Scale for Clozapine - Development and validation of a clozapine-specific side-effects scale | |
How change comes: translating biological research into care | |
Hyperprolactinaemia in first episode psychosis - A longitudinal assessment. | |
Immunity and schizophrenia: autoimmunity, cytokines, and immune responses | |
Impact of the demand for 'proxy assent' on recruitment to a randomised controlled trial of vaccination testing in care homes | |
Integrating interactive television-based psychiatric consultation into an urban community mental health service. | |
The interface of physical and mental health. | |
Is it possible for people with severe mental illness to sit less and move more? A systematic review of interventions to increase physical activity or reduce sedentary behaviour | |
Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series | |
Lower Bone Mineral Density at the Hip and Lumbar Spine in People with Psychosis Versus Controls: a Comprehensive Review and Skeletal Site-Specific Meta-analysis | |
The Maudsley practice guidelines for physical health conditions in psychiatry | |
Metabolic-inflammatory status as predictor of clinical outcome at 1-year follow-up in patients with first episode psychosis | |
Minocycline and the risk of acute psychiatric events in adolescence: A self-controlled case series | |
n 2014187088 | |
Need to bleed? Clozapine haematological monitoring approaches a time for change | |
Non-pharmacological interventions reduce antipsychotic-associated weight gain in outpatients | |
Opening Pandora's box in the UK: a hypothetical pharmacogenetic test for clozapine | |
Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis. | |
Pain is independently associated with reduced health related quality of life in people with psychosis | |
Patterns of illness and care over the 5 years following onset of psychosis in different ethnic groups; the GAP-5 study | |
Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability. | |
Physical health and schizophrenia, 2017 | |
Physical health problems in people with psychosis: The issue for informal carers | |
Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries | |
Predictors of falls and fractures leading to hospitalization in people with schizophrenia spectrum disorder: A large representative cohort study | |
The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: A systematic review and meta-analysis | |
Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls | |
Prevalence of serum N-methyl-d-aspartate receptor autoantibodies in refractory psychosis - ADDENDUM | |
Provision of health promotion programmes to people with serious mental illness: a mapping exercise of four South London boroughs. | |
Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotion | |
A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine | |
Reasons for cannabis use in first-episode psychosis: does strength of endorsement change over 12 months? | |
The relationship between prolactin levels and glucose homeostasis in antipsychotic-treated schizophrenic patients | |
Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies. | |
Review: limited evidence that adding a second antipsychotic improves clozapine treatment in schizophrenia | |
Schizophrenia as segmental progeria | |
Sedentary behaviour is associated with elevated C-reactive protein levels in people with psychosis | |
Serum prolactin and bone mineral density in schizophrenia | |
Serum zinc levels in patients with schizophrenia and their mothers | |
Sexual dysfunction in people with prodromal or first-episode psychosis. | |
Sodium valproate and clozapine induced neutropenia: A case control study using register data. | |
Soluble interleukin 2 receptor levels in families of people with schizophrenia | |
Strategies to deal with comorbid physical illness in psychosis. | |
Stress in medical students. | |
Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT | |
Substance use, medication adherence and outcome one year following a first episode of psychosis | |
Surgical Management of Obesity Among People with Schizophrenia and Bipolar Disorder: a Systematic Review of Outcomes and Recommendations for Future Research | |
Tobacco smoking and nicotine dependence in first episode and established psychosis | |
Treatment-refractory schizophrenia : a clinical conundrum | |
Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics | |
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology | |
Type 2 diabetes mellitus in people with severe mental illness: inequalities by ethnicity and age. Cross-sectional analysis of 588 408 records from the UK. | |
Unheard voices: outcomes of tertiary care for treatment-refractory psychosis. | |
The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge: A Systematic Review | |
Utilising symptom dimensions with diagnostic categories improves prediction of time to first remission in first-episode psychosis | |
The utility of the Mini-Mental State Examination in guiding assessment of capacity to consent to research | |
Variation in dose and plasma level of lamotrigine in patients discharged from a mental health trust | |
Vitamin-D Deficiency As a Potential Environmental Risk Factor in Multiple Sclerosis, Schizophrenia, and Autism | |
Vitamin D deficiency in first episode psychosis: a case-control study | |
モーズレイ精神科における身体疾患の診療ガイドライン |